; (2) the budget of the Committee for the following year; and (3) any other relevant information, including information on the membership of the Board, advisory committees, and the executive staff of the Committee, any conflicts of interest with respect to such individuals, and any bylaws adopted by the Board during the preceding year. 6. Requirements for entering into a licensing agreement (a) In general Upon retaining the title to any subject invention under section 202 of title 35, United States Code, or entering into a partial or exclusive licensing agreement relating to an applicable drug, the drug manufacturer shall agree to— (1) beginning one year after an applicable drug first comes to market, limit the annual price increase on such drug to the percentage by which the medical care consumer price index detailed expenditure category for all urban consumers for that year exceed such index for the preceding calendar year; (2) submit to the Drug Affordability and Access Committee, on a good faith timeline that is consistent with the recommendation under section 5(f)(2)(A)(ii)— (A) the manufacturer list price for the drug; (B) the retail price for the drug; (C) information on expenditures, including— (i) the total annual expenditures of the manufacturer on materials and manufacturing for the drug; (ii) the total expenditures of the manufacturer on acquiring patents and licensing for the drug, including expected royalty payments; (iii) the total expenditures of the manufacturer on research and development as shown on the manufacturer’s Federal tax returns under sections 41 and 174 of the Internal Revenue Code of 1986; (iv) the amount of the manufacturer's total expenditures derived from any Federal funding source, including tax deductions or credits claimed; and (v) total expected expenditures for marketing and advertising for the drug in the first 3 years that the drug is on the market; (D) the anticipated number of patients who will be treated with the drug